Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Xu, Dun Quan ^a,b   Luo, Ying ^b   Liu, Yi ^b   Wang, Jing ^b   Zhang, Bo ^b   Xu, Min ^b   Wang, Yan Xia ^b   Dong, Hai Ying ^b   Dong, Ming Qing ^b   Zhao, Peng Tao ^b   Niu, Wen ^b   Liu, Man Ling ^b   Gao, Yu Qi ^c   Li, Zhi Chao ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; ESTRADIOL; PROTEIN KINASE B; S PHASE KINASE ASSOCIATED PROTEIN 2;

AIRWAY REMODELING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE PRESSURE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; WESTERN BLOTTING; ANIMAL; ANOXIA; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; METABOLISM; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; ANOXIA; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; GENE EXPRESSION; HYPERTENSION, PULMONARY; MALE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 78650483925     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-182     Document Type: Article

References (68)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997, 336(2):111-117. 10.1056/NEJM199701093360207, 8988890.
2. Chazova I, Loyd JE, Zhdanov VS, Newman JH, Belenkov Y, Meyrick B. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am J Pathol 1995, 146(2):389-397. 1869854, 7856750.
3. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998, 352(9129):719-725. 10.1016/S0140-6736(98)02111-4, 9729004.
4. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30(20):2493-2537. 10.1093/eurheartj/ehp297, 19713419.
5. Rubin LJ. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 1995, 75(3):51A-54A. 10.1016/S0002-9149(99)80383-X, 7840055.
6. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 2000, 102(22):2781-2791.
7. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007, 30(1):104-109. 10.1183/09031936.00092306, 17360728.
8. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003, 361(9368):1533-1544. 10.1016/S0140-6736(03)13167-4, 12737878.
9. Ward JP, McMurtry IF. Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem. Curr Opin Pharmacol 2009, 9(3):287-296. 10.1016/j.coph.2009.02.006, 2692823, 19297247.
10. Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, McCarthy K, Golish JA, Stoller JK. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 2009, 104(9):1300-1306. 10.1016/j.amjcard.2009.06.048, 19840581.
11. Sunyer J, Anto JM, McFarlane D, Domingo A, Tobias A, Barcelo MA, Munoz A. Sex differences in mortality of people who visited emergency rooms for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158(3):851-856.
12. Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol 1981, 240(1):H62-H72.
13. Ou LC, Sardella GL, Leiter JC, Brinck-Johnsen T, Smith RP. Role of sex hormones in development of chronic mountain sickness in rats. J Appl Physiol 1994, 77(1):427-433.
14. Galie N, Palazzini M, Leci E, Manes A. Current Therapeutic Approaches to Pulmonary Arterial Hypertension. Rev Esp Cardiol 2010, 63(6):708-724.
15. Toshner M, Tajsic T, Morrell NW. Pulmonary hypertension: advances in pathogenesis and treatment. Br Med Bull 2010, 94:21-32. 10.1093/bmb/ldq012, 20447940.
16. Clarkson TB, Appt SE. Controversies about HRT--lessons from monkey models. Maturitas 2005, 51(1):64-74. 10.1016/j.maturitas.2005.02.016, 15883111.
17. Lahm T, Patel KM, Crisostomo PR, Markel TA, Wang M, Herring C, Meldrum DR. Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am J Physiol Endocrinol Metab 2007, 293(3):E865-E871. 10.1152/ajpendo.00201.2007, 17595218.
18. Studd J. Ten reasons to be happy about hormone replacement therapy: a guide for patients. Menopause Int 2010, 16(1):44-46. 10.1258/mi.2010.010001, 20424287.
19. Gardner JD, Murray DB, Voloshenyuk TG, Brower GL, Bradley JM, Janicki JS. Estrogen attenuates chronic volume overload induced structural and functional remodeling in male rat hearts. Am J Physiol Heart Circ Physiol 2010, 298(2):H497-H504. 10.1152/ajpheart.00336.2009, 19933421.
20. Mukundan H, Resta TC, Kanagy NL. 17Beta-estradiol decreases hypoxic induction of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 2002, 283(2):R496-R504.
21. Earley S, Resta TC. Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol 2002, 283(1):L86-L93.
22. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Tan J, Meldrum DR. Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 2008, 295(5):R1486-R1493. 2584849, 18832085.
23. Sherman TS, Chambliss KL, Gibson LL, Pace MC, Mendelsohn ME, Pfister SL, Shaul PW. Estrogen acutely activates prostacyclin synthesis in ovine fetal pulmonary artery endothelium. Am J Respir Cell Mol Biol 2002, 26(5):610-616.
24. Arnal JF, Douin-Echinard V, Tremollieres F, Terrisse AD, Sie P, Payrastre B, Guery JC, Bayard F, Gourdy P. Understanding the controversy about hormonal replacement therapy: insights from estrogen effects on experimental and clinical atherosclerosis. Arch Mal Coeur Vaiss 2007, 100(6-7):554-562.
25. Smith AM, Jones RD, Channer KS. The influence of sex hormones on pulmonary vascular reactivity: possible vasodilator therapies for the treatment of pulmonary hypertension. Curr Vasc Pharmacol 2006, 4(1):9-15. 10.2174/157016106775203090, 16472172.
26. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Weil B, Meldrum DR. Exogenous estrogen rapidly attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction. Shock 2008, 30(6):660-667. 10.1097/SHK.0b013e31816f239f, 18461023.
27. Earley S, Resta TC. Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol 2002, 283(1):L86-L93.
28. Rosano GM, Panina G. Oestrogens and the heart. Therapie 1999, 54(3):381-385.
29. Arnal JF, Laurell H, Lenfant F, Douin-Echinard V, Brouchet L, Gourdy P. Estradiol action in atherosclerosis and reendothelialization. Ernst Schering Found Symp Proc 2006, (1):69-86.
30. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006, 99(7):675-691. 10.1161/01.RES.0000243584.45145.3f, 17008597.
31. Gordon D, Reidy MA, Benditt EP, Schwartz SM. Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA 1990, 87(12):4600-4604. 10.1073/pnas.87.12.4600, 54164, 1972277.
32. Prabha M, Jin HF, Tian Y, Tang CS, DU JB. Mechanisms responsible for pulmonary hypertension. Chin Med J (Engl) 2008, 121(24):2604-2609.
33. Braun-Dullaeus RC, Mann MJ, Sedding DG, Sherwood SW, von der Leyen HE, Dzau VJ. Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler Thromb Vasc Biol 2004, 24(5):845-850. 10.1161/01.ATV.0000125704.28058.a2, 15016640.
34. Charron T, Nili N, Strauss BH. The cell cycle: a critical therapeutic target to prevent vascular proliferative disease. Can J Cardiol 2006, 22(Suppl B):41B-55B. 2780832, 16498512.
35. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13(12):1501-1512. 10.1101/gad.13.12.1501, 10385618.
36. Nakayama KI, Hatakeyama S, Nakayama K. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys Res Commun 2001, 282(4):853-860. 10.1006/bbrc.2001.4627, 11352628.
37. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994, 8(1):9-22. 10.1101/gad.8.1.9, 8288131.
38. Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res 2001, 3(2):91-94. 10.1186/bcr277, 139437, 11250752.
39. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009, 8(7):547-566. 10.1038/nrd2907, 19568282.
40. Tanner FC, Boehm M, Akyurek LM, San H, Yang ZY, Tashiro J, Nabel GJ, Nabel EG. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation 2000, 101(17):2022-2025.
41. Fouty BW, Grimison B, Fagan KA, Le CT, Harral JW, Hoedt-Miller M, Sclafani RA, Rodman DM. p27(Kip1) is important in modulating pulmonary artery smooth muscle cell proliferation. Am J Respir Cell Mol Biol 2001, 25(5):652-658.
42. Yu L, Quinn DA, Garg HG, Hales CA. Cyclin-dependent kinase inhibitor p27Kip1, but not p21WAF1/Cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice. Circ Res 2005, 97(9):937-945. 10.1161/01.RES.0000188211.83193.1a, 16195480.
43. Zhang H, Kobayashi R, Galaktionov K, Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995, 82(6):915-925. 10.1016/0092-8674(95)90271-6, 7553852.
44. Guo HQ, Pu XX, Guo CC, Rao HL, Li HR, Lin TY. The role of Skp2 in extranodal NK/T-cell lymphoma. Chin J Cancer 2010, 29(5):567-571.
45. Chan CH, Lee SW, Wang J, Lin HK. Regulation of Skp2 expression and activity and its role in cancer progression. ScientificWorldJournal 2010, 10:1001-1015.
46. Ecker K, Hengst L. Skp2: caught in the Akt. Nat Cell Biol 2009, 11(4):377-379. 10.1038/ncb0409-377, 19337320.
47. Zhu L. Skp2 knockout reduces cell proliferation and mouse body size: and prevents cancer?. Cell Res 2010, 20(6):605-607. 10.1038/cr.2010.71, 2990532, 20502441.
48. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464(7287):374-379. 10.1038/nature08815, 2928066, 20237562.
49. Duncan TJ, Al-Attar A, Rolland P, Harper S, Spendlove I, Durrant LG. Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer. Int J Gynecol Pathol 2010, 29(1):8-18. 10.1097/PGP.0b013e3181b64ec3, 19952944.
50. Zhou CH, Xiang M, He SY, Qian ZY. Crocetin inhibits cell cycle G(1)/S transition through suppressing cyclin D1 and elevating p27(kip1) in vascular smooth muscle cells. Phytother Res 2009,
51. Diez-Juan A, Castro C, Edo MD, Andres V. Role of the growth suppressor p27Kip1 during vascular remodeling. Curr Vasc Pharmacol 2003, 1(1):99-106. 10.2174/1570161033386709, 15320856.
52. van Tiel CM, Bonta PI, Rittersma SZ, Beijk MA, Bradley EJ, Klous AM, Koch KT, Baas F, Jukema JW, Pons D, et al. p27kip1-838C > A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity. Circulation 2009, 120(8):669-676. 10.1161/CIRCULATIONAHA.108.842179, 19667240.
53. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996, 271(5257):1861-1864. 10.1126/science.271.5257.1861, 8596954.
54. Kolodgie FD, Jacob A, Wilson PS, Carlson GC, Farb A, Verma A, Virmani R. Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol 1996, 148(3):969-976. 1861726, 8774151.
55. Suzuki A, Mizuno K, Ino Y, Okada M, Kikkawa F, Mizutani S, Tomoda Y. Effects of 17 beta-estradiol and progesterone on growth-factor-induced proliferation and migration in human female aortic smooth muscle cells in vitro. Cardiovasc Res 1996, 32(3):516-523.
56. Oparil S. Arthur C. Corcoran Memorial Lecture. Hormones and vasoprotection. Hypertension 1999, 33(1 Pt 2):170-176.
57. Dubey RK, Jackson EK. Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol 2001, 280(3):F365-F388.
58. Parker TA, Ivy DD, Galan HL, Grover TR, Kinsella JP, Abman SH. Estradiol improves pulmonary hemodynamics and vascular remodeling in perinatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2000, 278(2):L374-L381.
59. Lahm T, Crisostomo PR, Markel TA, Wang M, Weil BR, Novotny NM, Meldrum DR. The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone. Crit Care Med 2008, 36(7):2174-2183. 10.1097/CCM.0b013e31817d1a92, 18552699.
60. Sakao S, Tanabe N, Tatsumi K. The estrogen paradox in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2010, 299(4):L435-L438. 10.1152/ajplung.00057.2010, 20656892.
61. Tofovic SP. Estrogens and Development of Pulmonary Hypertension - Interaction of Estradiol MeAolism and Pulmonary Vascular Disease. J Cardiovasc Pharmacol 2010,
62. Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B, Dubey RK. 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res 2006, 99(3):266-274. 10.1161/01.RES.0000233318.85181.2e, 16794187.
63. Tofovic SP, Zhang X, Jackson EK, Zhu H, Petrusevska G. 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vascul Pharmacol 2009, 51(2-3):190-197. 10.1016/j.vph.2009.06.002, 2760300, 19540933.
64. Abidia A. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 2000, 27(8):630. 10.1046/j.1440-1681.2000.03310.x, 10901394.
65. Chen YF, Oparil S. Endothelin and pulmonary hypertension. J Cardiovasc Pharmacol 2000, 35(4 Suppl 2):S49-S53. 10.1097/00005344-200000002-00012, 10976782.
66. Aaronson PI, Robertson TP, Ward JP. Endothelium-derived mediators and hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol 2002, 132(1):107-120. 10.1016/S1569-9048(02)00053-8, 12126699.
67. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996, 98(1):36-42. 10.1172/JCI118774, 507398, 8690801.
68. Chakrabarti S, Lekontseva O, Peters A, Davidge ST. 17beta-Estradiol induces protein S-nitrosylation in the endothelium. Cardiovasc Res 2010, 85(4):796-805. 10.1093/cvr/cvp368, 19914929.